Supernus offers $402.5 million in convertible bonds

Supernus Pharmaceuticals Inc., a Rockville pharmaceutical company, on Thursday announced pricing of its private offering of $350 million of 0.625 percent convertible bonds due 2023.

To purchase a reprint of this article, contact reprints@thedailyrecord.com.

Leave a Reply

Your email address will not be published. Required fields are marked *